Marinus Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview

Marinus Pharmaceuticals

01/11/2024 14:14

* Marinus Pharmaceuticals Inc  MRNS.OQ   MRNS.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 5 (estimated) for the period ending January 1 0001
    * The Radnor Pennsylvania-based  company is expected to
report a
28.3% increase in revenue to $9.418 million from $7.34 million a
year ago, according to the mean estimate from 10 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Marinus Pharmaceuticals
Inc is
for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 7
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $2.00​, above​ its last closing price
of $0.30. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.59       -0.59      -0.60     Missed  -1.8
 Mar. 31 2024  -0.66       -0.66      -0.68     Missed  -2.8
 Dec. 31 2023  -0.62       -0.62      -0.74     Missed  -18.8​
 Sep. 30 2023  -0.65       -0.66      -0.61     Beat    7.7
 ​​Jan.        -0.69       -0.72      -0.61     Beat    14.9
 1 0001                                                 
 Mar. 31 2023  -0.71       -0.72      -0.67     Beat    7.3​
 Dec. 31 2022  -0.66       -0.70      -0.76     Missed  -9.1
 Sep. 30 2022  0.54        0.47       -0.94     Missed  -301.2
 This summary was machine generated November 1 at 14:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)